Arizona Research Center | Phoenix, AZ
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have body mass index (BMI) ≥30.0 kilograms per square meter (kg/m²), or ≥27.0 kg/m² with at least one of the following:
History of of at least one unsuccessful dietary effort to reduce body weight
GOA1 Inclusion Criteria:
GSA1 Inclusion Criteria:
GZBJ Addenda (2) inclusion criteria:
Exclusion criteria
GOA1 exclusion criteria
GSA1 exclusion criteria
GZBJ Addenda (2) exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2,300 participants in 5 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285- 4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal